Comparison the Safety and Pharmacokinetic Characteristics of DWP422 25 mg With Those of ENBREL 25MG PFS INJ. After Subcutaneous Injection in Healthy Male Volunteers

Phase 1 Unknown 38 enrolled Daewoong Pharmaceutical Co. LTD.

RandomizedDouble-blind

Summary

The purpose of this study was to compare the safety and pharmacokinetic characteristics of DWP422 25 mg with those of ENBREL 25MG PFS INJ. after subcutaneous injection in healthy male volunteers.

Timeline

Start: 2012-09
Primary completion: 2013-06
Completion: 2013-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	DWP422	Unknown	25 mg	Subcutaneous
Comparator	Etanercept	Protein / enzyme biologic	25 mg	Subcutaneous

Comparison the Safety and Pharmacokinetic Characteristics of DWP422 25 mg With Those of ENBREL 25MG PFS INJ. After Subcutaneous Injection in Healthy Male Volunteers

Summary

Timeline

Drugs

Indications